"Anti EGFR" trang 1 - tải miễn phí từ tailieunhanh
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response
9    53    1
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
11    90    1
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: Single institutional retrospective cohort study

Oral mucositis associated with anti-EGFR therapy in colorectal cancer: Single institutional retrospective cohort study
7    34    1
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients
11    42    1
REMARRY and PURSUIT trials: Liquid biopsyguided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer

REMARRY and PURSUIT trials: Liquid biopsyguided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
6    55    1
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
11    5    1
báo cáo khoa học:

báo cáo khoa học: " Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC"
7    48    0
Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model

Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model
13    64    1
The PANDA study: A randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

The PANDA study: A randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
11    78    1
MicroRNA-193a-3p is specifically downregulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer

MicroRNA-193a-3p is specifically downregulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer
14    33    1
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients
7    34    1
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
9    50    1
Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells

Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells
7    30    1
Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: A case report

Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: A case report
5    71    1
High mannose-binding Pseudomonas fluorescens lectin (PFL) downregulates cell surface integrin/EGFR and induces autophagy in gastric cancer cells

High mannose-binding Pseudomonas fluorescens lectin (PFL) downregulates cell surface integrin/EGFR and induces autophagy in gastric cancer cells
13    29    1
Can we accurately report PTEN status in advanced colorectal cancer

Can we accurately report PTEN status in advanced colorectal cancer
7    28    1
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: An effect mediated by EGFR inhibition, p53 acetylation and oxidative stress

Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: An effect mediated by EGFR inhibition, p53 acetylation and oxidative stress
14    38    1
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
10    36    1
Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer

Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer
10    45    1
Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer
11    13    1